Slayback Pharma Llc patents expiration
1. Prevduo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456354 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(14 years from now) | |
| US11110054 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(14 years from now) | |
Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
PREVDUO family patents
2. Testosterone Cypionate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11642355 | SLAYBACK PHARMA LLC | Pharmaceutical compositions of testosterone |
Mar, 2039
(14 years from now) | |
| US11311554 | SLAYBACK PHARMA LLC | Pharmaceutical compositions of testosterone |
Mar, 2039
(14 years from now) | |
Drugs and Companies using TESTOSTERONE CYPIONATE ingredient
Market Authorisation Date: 02 June, 2022
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR
More Information on Dosage
TESTOSTERONE CYPIONATE family patents
3. Vivimusta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844784 | SLAYBACK PHARMA LLC | Stable pharmaceutical compositions of bendamustine |
Jul, 2042
(18 years from now) | |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
VIVIMUSTA family patents